Consortium Focused on Hemophilia A Patients, Announces Significant Progress in Development of ‘First in World’ Regenerative Medicine Therapy

July 25th, 2017 The HemAcure Consortium, consisting of three European academic institutions, an enterprise for quality management and Ontario-based clinical stage regenerative medicine Company, Sernova Corp, reported significant scientific progress achieved in the development of a ‘first in world’ personalized regenerative medicine therapy for the...